Company intelligence / Profile preview

Jiya Acquisition Group

Palo Alto, California, United States

Ownership: Private
Development stage: Other

Overview

Jiya Acquisition Corp was a special purpose acquisition company formed to identify and merge with a target business, with an intended focus on biotechnology and pharmaceuticals. It did not itself operate a drug development, healthcare services, or life sciences platform business. The company completed a Nasdaq IPO in November 2020 under the symbol JYAC and was sponsored by Jiya Holding Company LLC, an affiliate of Samsara BioCapital. After failing to complete an initial business combination within its required timeframe, it redeemed its public shares effective November 25, 2022 and liquidated.

Industry: Investors

Partnerships

Samsara BioCapital

Beyond the preview

Go deeper on Jiya Acquisition Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiya Acquisition Group.

Explore the full profile